Success Metrics

Clinical Success Rate

62.5%

Based on 5 completed trials

Completion Rate

63%(5/8)

Active Trials

2(20%)

Results Posted

0%(0 trials)

Terminated

3(30%)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution10 total trials

Phase 1Safety & dosage

10(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(5)

Terminated(3)

Detailed Status

Completed5

Terminated3

Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

62.5%

Most Advanced

Phase 1

Trials by Phase

Phase 110 (100.0%)

Trials by Status

completed550%

active_not_recruiting220%

terminated330%

Recent Activity

2 active trials

Showing 5 of 10

active_not_recruitingphase_1

A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

NCT02988960

active_not_recruitingphase_1

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

NCT03893955

completedphase_1

A Study of ABT-165 in Subjects With Solid Tumors

NCT01946074

completedphase_1

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

NCT04223804

completedphase_1

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

NCT04196283

View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials

NCT02988960Phase 1

A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

Active Not Recruiting

NCT03893955Phase 1

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Active Not Recruiting

NCT01946074Phase 1

A Study of ABT-165 in Subjects With Solid Tumors

Completed

NCT04223804Phase 1

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

Completed

NCT04196283Phase 1

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Completed

NCT03071757Phase 1

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Completed

NCT03000257Phase 1

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

Completed

NCT03818542Phase 1

A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma

Terminated

NCT03035279Phase 1

A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer

Terminated

NCT03138408Phase 1

SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers